|
|
Volumn 306, Issue 5695, 2004, Pages 384-385
|
|
Withdrawal of Vioxx casts a shadow over COX-2 inhibitors
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CELECOXIB;
CYCLOOXYGENASE 1 INHIBITOR;
CYCLOOXYGENASE 2 INHIBITOR;
ETORICOXIB;
LUMIRACOXIB;
NAPROXEN;
PLACEBO;
PROSTACYCLIN;
ROFECOXIB;
THROMBOXANE;
VALDECOXIB;
LACTONE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
SULFONE;
ALZHEIMER DISEASE;
ARTHRITIS;
CANCER INHIBITION;
CLINICAL TRIAL;
COLON POLYP;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL SYMPTOM;
HEART FAILURE;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
NOTE;
PAIN;
PRIORITY JOURNAL;
STROKE;
THROMBOSIS;
ARTICLE;
BLOOD PRESSURE;
CEREBROVASCULAR ACCIDENT;
CHEMICALLY INDUCED DISORDER;
DRUG CONTROL;
DRUG EFFECT;
DRUG INDUSTRY;
POSTMARKETING SURVEILLANCE;
BLOOD PRESSURE;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIALS;
COLONIC POLYPS;
CYCLOOXYGENASE INHIBITORS;
DRUG AND NARCOTIC CONTROL;
DRUG INDUSTRY;
HUMANS;
LACTONES;
MYOCARDIAL INFARCTION;
PRODUCT SURVEILLANCE, POSTMARKETING;
SULFONES;
THROMBOSIS;
|
|
EID: 5644254327
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.306.5695.384 Document Type: Note |
|
Times cited : (118)
|
|
References (0)
|